18.04.2021
Andritz: International technology Group Andritz has successfully started up a new 500 t/d Herb chemical recovery boiler at Kuantum Papers Limited in Saila Khurd, Hoshiapur district in the state of Punjab, India. The boiler is designed to handle a mixture of hardwood and agro-based black liquor and enables environmentally friendly and more energy-efficient operation compared to a conventional boiler with direct contact evaporator. Thus, the mill’s pulp production as well as the power-to-heat-ratio are substantially increased. The boiler also features a unique vertical air system to minimize air emissions.
Andritz: weekly performance:
-1.21%
Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that out of the initially enrolled 64 patients, all 62 patients included in the treatment cycles have now concluded the Phase II clinical trial evaluating Tacrosolv eye drops in allergic rhinoconjunctivitis, i. e. hay fever affecting both the eyes and nose. The randomized, placebo controlled, double-blind phase II clinical trial was conducted at the Vienna Challenge Chamber (Austria) to assess safety and efficacy of two different dosages of Tacrosolv in a crossover design. Positive results provided, the Company plans to extend the ophthalmic use of Tacrosolv to further indications beyond allergic symptoms such as dry eye disease (keratoconjunctivitis sicca) and other types of ocular inflammation. “We are very pleased to conclude the active part of our phase II Tacrosolv. We are confident that the results will support our hypothesis that Tacrosolv is the first formulation of this highly potent immunosuppressant that allows for its use as an effective therapy in ocular inflammation,” said Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed. “Formulated with Marinosolv, we could achieve a more than 200-fold higher solubility compared to water enabling the use of tacrolimus in eye drops. Moreover, our formulation has a high local bioavailability – characteristics we have seen for several Marinosolv formulations so far.”